Effective and potentially retrievable: will leadless pacemakers become gold standard for pause prevention pacing? [0.03%]
有效且可取出的：无导线起搏器会成为停博预防起搏的金标准吗？
Silvia Magnani,Maria Giovanna Bucci,Hussam Alì et al.
Silvia Magnani et al.
Leadless pacemakers (LPMs) constitute a significant advancement in the management of bradyarrhythmias by eliminating complications associated with transvenous leads and subcutaneous pockets. Accumulating evidence demonstrates substantial cl...
The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive) [0.03%]
ODYSSEY-HCM和MAPLE-HCM研究：心脏肌球蛋白抑制剂在肥厚型心肌病（梗阻性和非梗阻性）中的作用
Elena Biagini,Maria Alessandra Schiavo
Elena Biagini
Hypertrophic cardiomyopathy (HCM) is an inherited heart disease characterized by unexplained left ventricular hypertrophy with or without outflow tract obstruction. Conventional therapies may relieve symptoms associated with left ventricula...
New frontiers in the treatment of hypercholesterolaemia: oral inhibition of PCSK9 [0.03%]
口服PCSK9抑制剂在治疗高胆固醇症中的新进展
Lorenzo Arnaboldi,Zixiong Tang,Nicola Ferri et al.
Lorenzo Arnaboldi et al.
PCSK9 inhibitors represent a cornerstone of lipid-lowering therapy; however, the need for cost containment and simplified routes of administration has stimulated the development of oral small molecules and peptidomimetics capable of modulat...
A leap into the future: excluding the ischaemic origin of chest pain through artificial intelligence [0.03%]
迈向未来——通过人工智能排除心绞痛的缺血性病因学起源
Fabrizio Imola,Michela Cece,Lucia Fatima di Napoli et al.
Fabrizio Imola et al.
Chest pain remains one of the most common and challenging presentations in cardiovascular medicine. Clinical evaluation-including structured history-taking, recognition of anginal equivalents, and focused physical examination-continues to a...
Coronary artery anomalies: contemporary approaches to risk stratification and management [0.03%]
冠状动脉异常的风险分层和管理的当代方法
Flavio Giuseppe Biccirè,Dario Mafrica,Matteo Mancinelli et al.
Flavio Giuseppe Biccirè et al.
The widespread adoption of coronary computed tomography angiography (CCTA) has led to a growing detection of coronary artery anomalies in contemporary clinical practice, often as incidental findings during the evaluation of suspected or kno...
Arturo Cesaro,Vincenzo Acerbo,Paolo Calabrò
Arturo Cesaro
Incretin-based therapies currently represent one of the cornerstones in the management of type 2 diabetes mellitus and obesity, owing to their ability to integratively modulate cardiometabolic risk. Semaglutide, a selective agonist of the g...
Role of transcatheter ablation in ischaemic ventricular tachycardia: should we be using it more? [0.03%]
缺血性室速的导管消融治疗：我们应该更加重视吗？
Stefano Bianchi,Filippo Maria Cauti
Stefano Bianchi
Ischaemic ventricular tachycardia (VT) represents a major cause of morbidity and mortality in patients with ischaemic heart disease. Transcatheter ablation has emerged as a complementary therapeutic strategy to implantable cardioverter-defi...
Gennaro Cice
Gennaro Cice
In the collective perception, uraemic patients are often identified as those undergoing dialysis. In reality, however, dialysis patients represent only a small fraction of the total uraemic population. Conservative estimates indicate that o...
Use of vericiguat in the VICTOR trial: a study that is difficult to interpret [0.03%]
VICTOR研究中的维立西呱使用：一项难以解读的研究
Francesco Orso,Christian Basile
Francesco Orso
Vericiguat is a soluble guanylate cyclase stimulator that acts by restoring the nitric oxide-cyclic guanosine monophosphate pathway, which is markedly impaired in heart failure with reduced ejection fraction (HFrEF). The VICTORIA trial demo...
How much does eliminating one or two cardiovascular risk factors matter?: Evidence from the Global Cardiovascular Risk Consortium [0.03%]
消除一个或两个心血管危险因素重要吗？：来自全球心血管风险联盟的证据
Roberto Spoladore,Stefano Pedroli,Andrea Tacchetto et al.
Roberto Spoladore et al.
Five modifiable cardiovascular risk factors-hypertension, diabetes, smoking, hypercholesterolemia, and obesity-account for approximately 50% of the global burden of cardiovascular disease. Recent data from the Global Cardiovascular Risk Con...